Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBT: 2021-2025

Historic EBT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $27.2 million.

  • Kiniksa Pharmaceuticals International's EBT rose 477.13% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 153.31%. This contributed to the annual value of -$36.2 million for FY2024, which is 60.33% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's EBT is $27.2 million, which was up 18.71% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBT registered a high of $90.9 million during Q4 2022, and its lowest value of -$72.0 million during Q4 2023.
  • For the 3-year period, Kiniksa Pharmaceuticals International's EBT averaged around -$5.6 million, with its median value being -$7.2 million (2024).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's EBT slumped by 179.24% in 2023 and then skyrocketed by 892.93% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's EBT stood at -$43.8 million in 2021, then spiked by 307.56% to $90.9 million in 2022, then crashed by 179.24% to -$72.0 million in 2023, then skyrocketed by 76.43% to -$17.0 million in 2024, then spiked by 477.13% to $27.2 million in 2025.
  • Its EBT stands at $27.2 million for Q3 2025, versus $22.9 million for Q2 2025 and $15.6 million for Q1 2025.